ml7

ML-7 hydrochloride (ML-7 HCl) 是一种可渗透细胞的、可逆的、有效的、ATP 竞争性的肌球蛋白轻链激酶(MLCK) 特异性抑制剂，IC50为300 nM。它还抑制平滑肌肌球蛋白轻链激酶、PKA 和 PKC。

ML 7 is an inhibitor of myosin light chain kinase that protects cardiac function from ischemia reperfusion (I R) injury.

(S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor (IC50: 0.6 μM on BCRP efflux transporter).

EML741 also inhibits DNMT1 (IC50, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated. EML741 is a histone lysine methyltransferase G9a GLP inhibitor, with an IC50 of 23 nM, Kd of 1.13 μM for G9a.

ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions. ML753286 is an orally active and selective inhibitor of BCRP (IC50: 0.6 μM). It is also stable in plasma across species.

(6R)-ML753286 是 ML753286 的异构体。ML753286 是一种口服活性和选择性 BCRP(抗乳腺癌蛋白) 抑制剂，IC50为 0.6 μM。 ML753286 在啮齿动物和人类肝脏 S9 组分中具有高渗透性和低至中等清除率，并且在不同物种中都具有血浆稳定性。

EML734为PRMT7 9的选择性抑制剂，其对PRMT7的IC50为315 nM，对PRMT9的IC50为0.89 μM。

ML-792 是特异性的小泛素样修饰物活化酶（SUMO）抑制剂。ML-792选择性抑制SAE SUMO1和SAE SUMO2，IC50分别为 3 和 11 nM。